- ►diabetesjournals.org N Satoh, Y Ogawa, T Usui, T Tagami, S Kono, H … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 136 Japanese type 2 diabetic patients were
included and divided into two groups: the pioglitazone-treated group (30 mg daily for 3
months) (n = 70) and the untreated control group (n = 66). The changes in glycolipid ... Cited by 254 - Related articles - BL Direct - All 5 versions
- ►endojournals.org [PDF] H Koshiyama, D Shimono, N Kuwamura, J … - Journal of Clinical …, 2001 - Endocrine Soc 3454 RAPID COMMUNICATIONS JCE & M • 2001 Vol. 86 • No. 7 Multiple regression analysis
indicated that there was no statistically significant relation between a decrease in IMT and those
in HbAlc. DISCUSSION The present study indicated that pioglitazone has an inhibitory ... Cited by 381 - Related articles - BL Direct - All 5 versions
- ►ahajournals.org MR Langenfeld, T Forst, C Hohberg, P Kann, G Lubben … - Circulation, 2005 - Am Heart Assoc Methods and Results— We compared the effects of pioglitazone-based therapy (45 mg/d) and
glimepiride-based treatment (2.7±1.6 mg/d) for 12 and 24 weeks on metabolic control (HbA 1c
), insulin resistance (homeostasis model assessment), and carotid IMT (B-mode ... Cited by 188 - Related articles - All 14 versions
- ►ahajournals.org SM Haffner, AS Greenberg, WM Weston, H Chen, K … - Circulation, 2002 - Am Heart Assoc Background— Markers of systemic inflammation (eg, C-reactive protein [CRP] and
interleukin-6 [IL-6]) have been proposed to be "nontraditional" risk factors for cardiovascular
disease in patients with type 2 diabetes mellitus. Matrix metalloproteinase-9 (MMP-9) has ... Cited by 837 - Related articles - BL Direct - All 9 versions
- ►onlinejacc.org A Pfützner, N Marx, G Lübben, M Langenfeld, D … - Journal of the American …, 2005 - Elsevier A total of 192 patients were enrolled into a six-month, prospective, open-label, controlled clinical
study. They were randomized to receive either pioglitazone (45 mg) or glimepiride (1 to 6
mg, with the intent to optimize therapy). Biochemical and clinical markers to assess ... Cited by 177 - Related articles - All 18 versions
- ►diabetesjournals.org F Pistrosch, J Passauer, S Fischer, K Fuecker, M … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Glycemic control was comparable under rosiglitazone and nateglinide. Rosiglitazone
ameliorated insulin resistance by 60% compared with nateglinide. ACh response was significantly
increased after rosiglitazone treatment (maximum forearm blood flow 12.8 ± 1.3 vs. 8.8 ± ... Cited by 175 - Related articles - BL Direct - All 5 versions
- ►ahajournals.org JS Sidhu, Z Kaposzta, HS Markus, JC … - … , thrombosis, and vascular …, 2004 - Am Heart Assoc Methods and Results— Consecutive subjects (n=92) with clinically stable, angiographically documented
CAD and without diabetes mellitus were randomized in a double-blind manner to receive placebo
or rosiglitazone for 48 weeks. They received single-dose placebo and rosiglitazone 4 mg ... Cited by 222 - Related articles - BL Direct - All 9 versions
TD Wang, WJ Chen, JW Lin, MF Chen, YT Lee - The American journal of …, 2004 - Elsevier Fifty nondiabetic patients who met a modified National Cholesterol Education Program definition
for the metabolic syndrome were randomized to receive either rosiglitazone (4 mg/day; N =
25) or placebo (n = 25) for 8 weeks. Compared with those receiving placebo, patients in ... Cited by 152 - Related articles - All 10 versions
A Raji, EW Seely, SA Bekins, GH Williams, DC … - Diabetes care, 2003 - Am Diabetes Assoc RESULTS—There was no change in fasting plasma glucose (83 ± 2 vs. 82 ± 2 mg/dl, P =
0.60), but fasting insulin decreased (16.1 ± 1.4 vs. 12.5 ± 0.9 μU/ml, P < 0.01). Total glucose
disposal during the clamp increased (5.0 ± 0.4 vs. 5.9 ± 0.5 mg · kg −1 · min −1 , P < ... Cited by 233 - Related articles - BL Direct - All 8 versions
S Fullert, F Schneider, E Haak, H Rau, K … - Journal of Clinical …, 2002 - Endocrine Soc Hypertension is often associated with insulin resistance, dyslipidemia and obesity, which indicate
a prediabetic state and increased risk of cardiovascular disease. Pioglitazone treatment of patients
with type 2 diabetes reduces insulin resistance and improves lipid profiles. The present ... Cited by 118 - Related articles - All 7 versions
